Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Neumora Therapeutics (NMRA) had its "buy" rating reaffirmed by Guggenheim. They now have a $14.00 price target on the stock.
Neumora Therapeutics (NMRA) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]